Synaptogenix Inc (SNPX)

[InTheTrenches]

Good insights.

The article is definitely worth a read.

There was an important discussion in the article about why large pharma and industry analysts are skeptical of small cap bio results in AD:

ACAD recently ran trials on Nuplazid (pimavanserin) in AD psychosis. They reported positive results in a trial, but while the NPI-NH scores were statistically significant at week 6, they weren't significant at week 12. (According to the Endpoints article, 12 weeks is an industry standard for success; explains why Bryostatin injections are run for 12-15 weeks.) Later, when all the clinical endpoints were revealed, the statistical significance at week 6 was due to a drop in placebo at week 6.